Compare D R Horton Inc (DHI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Smith & Nephew plc — how do they compare? D R Horton Inc trades at $134.5 (market cap $37.99B), while Smith & Nephew plc trades at $27.11 (market cap $11.10B). The key difference: D R Horton Inc is far larger — about 3.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Smith & Nephew plc for 120 Days on average.
| DHI | SNN | |
|---|---|---|
Market Cap | $37.99B | $11.10B |
Volume | 2,974,460 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $37.17 |
52-Week Low | $132.53 | $26.42 |
Typical Hold Time | 46 Days | 120 Days |
Enterprise Value | $43.09B | $14.13B |
Dividend Yield | 1.33% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $133.28, down 2.54% on the day amid broader housing sector weakness. The stock shows bearish technical signals with oversold RSI conditions, while fundamentals remain solid with consistent earnings beats and attractive valuation multiples. Recent news highlights pressure from rising mortgage rates and housing market concerns, though the company maintains strong operational cash flow and analyst support.
DHI presents a value opportunity with below-market P/E of 12.95 and 47% analyst buy ratings, but faces headwinds from potential 9% mortgage rates and declining home sales. The consensus price target of $156.57 offers 17% upside, though investors should monitor Q3 2026 earnings on October 29 for margin sustainability.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
